Giles H G, Corrigall W A, Khouw V, Sellers E M
Clin Pharmacol Ther. 1982 Jan;31(1):77-82. doi: 10.1038/clpt.1982.12.
In healthy male subjects (n = 12) phencyclidine (PCP) free fraction was 22.0 +/- 2.8 % (mean +/- SD). In male patients with mild to moderate alcoholic liver disease (n = 16) free fraction (23.0 +/- 3.4%) was of the same order as in healthy subjects although age and the concentrations of albumin, bilirubin, and high-density lipoproteins were different (P less than 0.05). Free fraction (76.2 /+- 0.06%) in fatty acid free human serum albumin (HSA, 4.4 gm/dl) was far greater than in plasma. Both the increased binding of PCP in plasma over HSA and the lack of a difference in PCP binding between normals and patients was associated with alpha 1-acid glycoprotein (alpha 1-AGP). This protein is an acute-phase reactant that binds cationic drugs and rises nonspecifically in a variety of diseases. Free fraction of PCP in alpha 1-AGP (75 mg/dl) was 36.4 +/- 1.7%. Half of the variance in PCP binding can be accounted for (r = 0.67, P less than 0.01) from percentage of free PCP = 39.24 - 2.18 (albumin) - 0.094 (alpha 1-AGP). Male rats (n = 14, weight = 251 +/- 7 gm) were alternatively assigned to pretreatment with either saline or alpha 1-AGP (11.6 mg) by cardiac puncture. PCP brain concentrations were reduced (11%, P less than 0.05) in the protein-treated group 5 min after cardiac 3H-PCP (0.17 mg) administration, demonstrating that increased plasma protein binding can reduce free drug concentration during the distribution phase and, thereby, the rate and extent of drug distribution.
在健康男性受试者(n = 12)中,苯环己哌啶(PCP)的游离分数为22.0±2.8%(平均值±标准差)。在患有轻度至中度酒精性肝病的男性患者(n = 16)中,尽管年龄以及白蛋白、胆红素和高密度脂蛋白的浓度不同(P<0.05),但其游离分数(23.0±3.4%)与健康受试者处于同一水平。在无脂肪酸的人血清白蛋白(HSA,4.4 g/dl)中,游离分数(76.2±0.06%)远高于血浆中的游离分数。PCP在血浆中相对于HSA的结合增加以及正常人与患者之间PCP结合无差异均与α1-酸性糖蛋白(α1-AGP)有关。这种蛋白质是一种急性期反应物,可结合阳离子药物,并在多种疾病中无特异性升高。在α1-AGP(75 mg/dl)中PCP的游离分数为36.4±1.7%。PCP结合的方差中有一半可由游离PCP百分比=39.24 - 2.18(白蛋白)- 0.094(α1-AGP)来解释(r = 0.67,P<0.01)。将雄性大鼠(n = 14,体重 = 251±7 g)交替分配通过心脏穿刺用生理盐水或α1-AGP(11.6 mg)进行预处理。在给予心脏3H-PCP(0.17 mg)后5分钟,蛋白质处理组中的PCP脑浓度降低(11%,P<0.05),表明血浆蛋白结合增加可在分布阶段降低游离药物浓度,从而降低药物分布的速率和程度。